89bio, Inc.
Clinical trials sponsored by 89bio, Inc., explained in plain language.
A clinical-stage biopharmaceutical company developing therapies for liver and metabolic diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New drug aims to reverse liver damage in MASH cirrhosis
Disease control Recruiting nowThis Phase 3 study tests an experimental drug called pegozafermin in 762 adults with liver scarring (cirrhosis) caused by MASH, a fatty liver disease. Participants receive weekly injections of the drug or a placebo for about two years. The goal is to see if the drug can improve l…
Phase: PHASE3 • Sponsor: 89bio, Inc. • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New drug could reverse liver scarring in MASH patients
Disease control Recruiting nowThis study tests a new drug, pegozafermin, in 1,350 adults with MASH (a type of fatty liver disease) and moderate liver scarring (stage F2 or F3). The goal is to see if the drug can improve scarring or resolve liver inflammation without making the disease worse over 52 weeks. Par…
Phase: PHASE3 • Sponsor: 89bio, Inc. • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC